Shots:Chiesi Group has entered into an exclusive global collaboration & license deal with Arbor for ABO-101 in primary hyperoxaluria type 1 (PH1) & a multitarget option to use Arbor’s gene editing platform for developing liver-targeted therapies for rare diseasesAs per the deal, Chiesi will obtain exclusive rights to develop & commercialize ABO-101 for PH1…
The peptide therapeutics market in North America and beyond is evolving fast, and 2025 is set to be a groundbreaking year.Whether you’re a researcher involved in peptide drug clinical trials, an investor in different pharmaceutical companies, or just curious about the future of medicine and drug discovery, understanding various peptide therapeutics market trends will…
Shots: Gaucher disease is a rare, autosomal recessive disorder that enlarges organs like the bone marrow, liver, and spleen by depositing fats (lipids) in them In this reprise of our Disease of the Month report, we present an enlightening description of Gaucher disease with a thorough study of epidemiology, market size, disease management, potential medicines,…
Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, and China. This month’s report includes 10 biological drugs, 15 small molecules, 5 cell and gene therapies, 4 devices, 1 vaccine and 1 microbiota MicuRx’ Contezolid and Contezolid acefosamil, focused on the treatment of Diabetic…
Shots:Monoclonal antibodies are transforming therapeutics through their highly efficient targeting mechanisms. There is a wide range of uses for monoclonal antibodies, including diagnosis, therapy, and researchIn 2021, the monoclonal antibody therapy market size was valued at $178.5B and is envisioned to reach $451.89B by 2028, displaying a CAGR of 14.1%. Humira was the…
Shots:Martin shared his views on the appointment of Jonathan I. Lieber as the CFO of Rallybio. Martin spoke about Jonathan's educational background and experience while talking to PharmaShots' teamHe also talked about how Jonathan I. Lieber’s expertise in finance, capital raising, long-range strategic planning, operations, and investor relations can contribute to the long-term…
In an interview with PharmaShots, Martina Flammer, Chief Medical Officer at Insmed share her views on the R&D continuum to develop new drugs for rare diseases and also highlights its business pillarsShots:The idea of the continuum is that all department works together to develop the drugs which will be helpful not only for the company but for patients tooIn…

